Market Cap 18.22M
Revenue (ttm) 1.98M
Net Income (ttm) -9.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -486.36%
Debt to Equity Ratio 0.00
Volume 93,100
Avg Vol 473,510
Day's Range N/A - N/A
Shares Out 8.24M
Stochastic %K 21%
Beta 0.50
Analysts Hold
Price Target $6.00

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the ma...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
brunoq14
brunoq14 May. 19 at 2:31 PM
$LPCN A bit of a mindless selloff is going on. Not every stock, but quite a few.
0 · Reply
ultistock
ultistock May. 19 at 2:14 PM
$LPCN My email alerts from LPCN stopped working. Has that happened to anyone else?
1 · Reply
brunoq14
brunoq14 May. 19 at 12:29 PM
$LPCN Not only do we have 1154 data presentation on May 26, we also have a fireside chat scheduled on May 20. Check out the Lipocine website message board.
0 · Reply
TradeOrGoHome
TradeOrGoHome May. 19 at 12:09 PM
$LPCN loaded. This will see $7.
1 · Reply
DARKP00L
DARKP00L May. 19 at 12:08 PM
$LPCN 08:04 on May. 19 2026 Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26 #tradeideas
0 · Reply
amazingcrwns
amazingcrwns May. 18 at 3:15 PM
$LPCN Friendly reminder of what the data looks like when you exclude the outlier site.
2 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 13 at 6:25 PM
$LPCN Ultra-rare Stegosaurus trading pattern taking shape today. Could be Ultra-bullish if doesn't go extinct first.
1 · Reply
RunningRobert1
RunningRobert1 May. 11 at 2:48 PM
$LPCN Lipocine Inc LPCN Q1 2026 Summary 11May2026 https://youtu.be/hw_FiiFoiv4 Boring Q report, but interesting Corporate presentation, dont know if it will lead to anything but it def at least clears the way for LPCN to try another trial, paying for that trial...well we will see
1 · Reply
joe77w
joe77w May. 8 at 7:26 AM
$LPCN 3.4 USD in net equity, add pipeline, this seems way undervalued, according Just issued 10Q.
1 · Reply
amazingcrwns
amazingcrwns May. 7 at 7:47 PM
$LPCN Earnings report is out, as is the new corporate deck on the website. There is additional statistical information from the ppd trial. There is more data to support oral brex, but I'm angry about it.
2 · Reply
Latest News on LPCN
Lipocine Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 12 days ago

Lipocine Quarterly report: Q1 2026


Lipocine Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 12 days ago

Lipocine Earnings release: Q1 2026


Lipocine Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 12 days ago

Lipocine Slides: Corporate presentation


Lipocine Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 weeks ago

Lipocine Proxy statement: Proxy filing


Lipocine Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 weeks ago

Lipocine Proxy statement: Proxy filing


Lipocine Slides: Investor presentation

Apr 13, 2026, 7:00 AM EDT - 5 weeks ago

Lipocine Slides: Investor presentation


Lipocine downgraded to Neutral from Buy at H.C. Wainwright

2026-04-06T10:16:57.000Z - 6 weeks ago

Lipocine downgraded to Neutral from Buy at H.C. Wainwright


Lipocine Slides: Corporate presentation

Apr 2, 2026, 7:00 AM EDT - 6 weeks ago

Lipocine Slides: Corporate presentation


Lipocine Earnings release: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Lipocine Earnings release: Q4 2025


Lipocine Annual report: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Lipocine Annual report: Q4 2025


Lipocine Slides: Corporate presentation

Feb 18, 2026, 6:00 AM EST - 3 months ago

Lipocine Slides: Corporate presentation


Lipocine price target raised to $15 from $7 at H.C. Wainwright

2026-01-21T11:15:46.000Z - 4 months ago

Lipocine price target raised to $15 from $7 at H.C. Wainwright


Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

2025-12-16T13:06:09.000Z - 5 months ago

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone


Lipocine price target lowered to $7 from $8 at H.C. Wainwright

2025-11-13T11:20:38.000Z - 6 months ago

Lipocine price target lowered to $7 from $8 at H.C. Wainwright


Lipocine reports Q3 EPS (59c) vs. (44c) last year

2025-11-06T13:06:28.000Z - 6 months ago

Lipocine reports Q3 EPS (59c) vs. (44c) last year


Lipocine Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 6 months ago

Lipocine Earnings release: Q3 2025


Lipocine Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 6 months ago

Lipocine Quarterly report: Q3 2025


Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 7 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®


Lipocine reports Q2 EPS (41c) vs. (57c) last year

2025-08-05T12:05:16.000Z - 10 months ago

Lipocine reports Q2 EPS (41c) vs. (57c) last year


Lipocine Quarterly report: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Lipocine Quarterly report: Q2 2025


Lipocine Earnings release: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Lipocine Earnings release: Q2 2025


Lipocine Transcript: Status Update

Jul 9, 2025, 11:00 AM EDT - 11 months ago

Lipocine Transcript: Status Update


Lipocine announces filing of NDA for TLANDO in Canada

2025-06-09T12:10:36.000Z - 1 year ago

Lipocine announces filing of NDA for TLANDO in Canada


Lipocine assumed with a Buy at H.C. Wainwright

2025-05-29T14:45:19.000Z - 1 year ago

Lipocine assumed with a Buy at H.C. Wainwright


Lipocine Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Lipocine Earnings release: Q1 2025


Lipocine Quarterly report: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Lipocine Quarterly report: Q1 2025


Lipocine announces license and supply agreement with Ache

2025-05-06T12:17:57.000Z - 1 year ago

Lipocine announces license and supply agreement with Ache


Lipocine Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Lipocine Proxy statement: Proxy Filing


Lipocine Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Lipocine Proxy statement: Proxy Filing


Lipocine initiates Phase 3 trial for LPCN 1154

2025-03-26T12:06:51.000Z - 1 year ago

Lipocine initiates Phase 3 trial for LPCN 1154


Lipocine Earnings release: Q4 2024

Mar 13, 2025, 11:30 AM EDT - 1 year ago

Lipocine Earnings release: Q4 2024


Lipocine Annual report: Q4 2024

Mar 13, 2025, 11:30 AM EDT - 1 year ago

Lipocine Annual report: Q4 2024


Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154


Lipocine Press release: Corporate Presentation

Dec 12, 2024, 7:00 PM EST - 1 year ago

Lipocine Press release: Corporate Presentation


Lipocine Quarterly report: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Lipocine Quarterly report: Q3 2024


Lipocine Earnings release: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Lipocine Earnings release: Q3 2024


Lipocine Transcript: Status Update

Oct 15, 2024, 6:00 PM EDT - 1 year ago

Lipocine Transcript: Status Update


Lipocine Slides: Status Update

Oct 15, 2024, 6:00 PM EDT - 1 year ago

Lipocine Slides: Status Update


Lipocine Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Lipocine Quarterly report: Q2 2024


Lipocine Earnings release: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Lipocine Earnings release: Q2 2024


Lipocine Proxy statement: Proxy Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Lipocine Proxy statement: Proxy Filing


Lipocine Quarterly report: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Lipocine Quarterly report: Q1 2024


Lipocine Earnings release: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Lipocine Earnings release: Q1 2024


Lipocine Registration statement: Registration Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Lipocine Registration statement: Registration Filing


Lipocine Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Lipocine Proxy statement: Proxy Filing


Lipocine Transcript: Study Result

Apr 10, 2024, 6:00 PM EDT - 2 years ago

Lipocine Transcript: Study Result


Lipocine Annual report: Q4 2023

Mar 6, 2024, 6:00 PM EST - 2 years ago

Lipocine Annual report: Q4 2023


Lipocine Earnings release: Q4 2023

Mar 6, 2024, 6:00 PM EST - 2 years ago

Lipocine Earnings release: Q4 2023


Lipocine to Present at 36th Annual Roth Conference

Mar 6, 2024, 8:00 AM EST - 2 years ago

Lipocine to Present at 36th Annual Roth Conference


brunoq14
brunoq14 May. 19 at 2:31 PM
$LPCN A bit of a mindless selloff is going on. Not every stock, but quite a few.
0 · Reply
ultistock
ultistock May. 19 at 2:14 PM
$LPCN My email alerts from LPCN stopped working. Has that happened to anyone else?
1 · Reply
brunoq14
brunoq14 May. 19 at 12:29 PM
$LPCN Not only do we have 1154 data presentation on May 26, we also have a fireside chat scheduled on May 20. Check out the Lipocine website message board.
0 · Reply
TradeOrGoHome
TradeOrGoHome May. 19 at 12:09 PM
$LPCN loaded. This will see $7.
1 · Reply
DARKP00L
DARKP00L May. 19 at 12:08 PM
$LPCN 08:04 on May. 19 2026 Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26 #tradeideas
0 · Reply
amazingcrwns
amazingcrwns May. 18 at 3:15 PM
$LPCN Friendly reminder of what the data looks like when you exclude the outlier site.
2 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 13 at 6:25 PM
$LPCN Ultra-rare Stegosaurus trading pattern taking shape today. Could be Ultra-bullish if doesn't go extinct first.
1 · Reply
RunningRobert1
RunningRobert1 May. 11 at 2:48 PM
$LPCN Lipocine Inc LPCN Q1 2026 Summary 11May2026 https://youtu.be/hw_FiiFoiv4 Boring Q report, but interesting Corporate presentation, dont know if it will lead to anything but it def at least clears the way for LPCN to try another trial, paying for that trial...well we will see
1 · Reply
joe77w
joe77w May. 8 at 7:26 AM
$LPCN 3.4 USD in net equity, add pipeline, this seems way undervalued, according Just issued 10Q.
1 · Reply
amazingcrwns
amazingcrwns May. 7 at 7:47 PM
$LPCN Earnings report is out, as is the new corporate deck on the website. There is additional statistical information from the ppd trial. There is more data to support oral brex, but I'm angry about it.
2 · Reply
DivvyDoo
DivvyDoo May. 6 at 4:14 PM
$LPCN interesting that SPTX is actually 53M shares OS close to 850M MC. Management team ex -Karuna. Glyph vs Lipral.
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER May. 6 at 3:16 PM
$LPCN There's gold in them hills.
0 · Reply
BillionerOfKing
BillionerOfKing May. 4 at 9:32 AM
$LPCN Current Stock Price: $2.35
2 · Reply
DivvyDoo
DivvyDoo May. 2 at 2:50 PM
$LPCN Seaport IPO - valued around 280M - https://seaporttx.com/our-pipeline/
0 · Reply
steven1x
steven1x Apr. 30 at 7:54 PM
$LPCN https://g.co/gemini/share/8ef478f5edba
1 · Reply
BaneMan666
BaneMan666 Apr. 24 at 9:55 PM
$LPCN Lipocine’s FAST ACTING SAFE oral drug for the most severe psychiatric disorder patients is best option! The FDA announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. It's a significant step toward supporting psychedelic-based medicines for conditions such as treatment-resistant depression, PTSD and other substance use disorders, the agency said. The FDA also said allowing these studies to proceed does not mean the drugs are approved or proven safe and effective and that data must be closely monitored.
1 · Reply
amazingcrwns
amazingcrwns Apr. 24 at 1:15 PM
$LPCN Not much happening here for the next several weeks. I'm looking forward to the earnings report for the latest financials after ATM usage and maybe some indication of what their plans are, and then maybe a new slide deck before the annual meeting on June 3rd. I believe its still several weeks before they'll complete their full analysis of the data and submit it to the FDA. Its probably a similar timeline for them to get a response to the FastTrack and BTD applications. Then another few months for the FDA to review the complete dataset and give a response. Probably going to be a quiet summer, hopefully we get canadian approval for Tlando at some point and maybe they'll sign a new regional supplier deal or something.
1 · Reply
bg4
bg4 Apr. 22 at 6:35 PM
$LPCN Dr. R. Dana Ono's background strongly suggests that he is a specialist in preparing companies for sale or strategically repositioning them.
4 · Reply
frontiere
frontiere Apr. 22 at 2:16 PM
$NEUP Neuphoria ex $BNOX Bionomics — Long — anyone here picked up on CEO Spyros resigning from his $LPCN Lipocine Chairmanship with a disagreement? Breadcrumbs, but I see it as a small good sign — I was a bit wary of how actively he is involved in NEUP right now. Also LPCN is an interesting cigar butt long if goes <$2.00 again ;)
1 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 8:30 PM
$LPCN Lipocine Appoints R. Dana Ono As Chairman Of The Board On April 20, 2026
2 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 2:36 PM
$LPCN Bullish MACD crossover on daily. Mega gap over 2.63 NOTE: Insiders purchased recently a ton of shares $434,600 in total value
1 · Reply